Intranasal Vaccine: Bharat Biotech Seeks Approval for Phase 3 Trials

Bharat Biotech seeks approval from the Drug Controller General of India (DCGI) to conduct Phase 3 trials of intranasal vaccine.

The Hyderabad-based vaccine maker has submitted the application and awaiting approval for Phase 3 trials of intranasal vaccine (BBV154).

‘Covaxin and Covishield are the vaccines being used in India in the vaccination drive. However, using intranasal vaccine, as a booster dose can prevent Covid-19 virus transmission better.’

Tweet it Now

"Intranasal vaccines have the potential to prevent against transmission. An intranasal vaccine as a booster dose will be easier to administer in mass vaccination campaigns," a source told IANS.

Sources said Phase 2 trials were conducted with Covaxin and BBV154. "Using a combination of one intramuscular and the other nasal is an innovative approach of heterologous," they said.

The intranasal vaccine can be given as booster dose to those who have already taken both the doses of intramuscular vaccines.

COVID-19: Nasal Vaccine can Be Potential Gamechanger
Intranasal vaccines for coronavirus administered through nose can be a potential gamechanger in Indias fight against the coronavirus pandemic.

Health experts say the intranasal vaccine as booster dose will add a key weapon in India’s fight against COVID-19, especially when Omicron, the new variant, spreads fast in the country.

Bharat Biotech’s Covaxin, along with Covishield manufactured by Serum Institute of India, are the two vaccines so far being used in India’s current COVID-19 vaccination drive, which was launched in January this year.

Intranasal Vaccine Trials Begin in India
India's first intranasal vaccine against Covid has began it's phase 2 trials. The vaccine is dropped into the nostril and it gradually slips into the respiratory tract, where the vaccine neutralizes the virus in the nostril itself and prevents it from penetrating into the respiratory tract.

Russian vaccine Sputnik-V has also been approved for emergency use in India.

Covid-19 can End in 2022: WHO Chief
Director-General of the World Health Organization (WHO) Tedros Adhanom Ghebreyesus has called on the world to work together to end the Covid-19 pandemic within the next year.

Source-IANS